<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Gen Thorac Cardiovasc Surg Cases</journal-id><journal-id journal-id-type="iso-abbrev">Gen Thorac Cardiovasc Surg Cases</journal-id><journal-title-group><journal-title>General Thoracic and Cardiovascular Surgery Cases</journal-title></journal-title-group><issn pub-type="epub">2731-6203</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863716</article-id><article-id pub-id-type="publisher-id">190</article-id><article-id pub-id-type="doi">10.1186/s44215-025-00190-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Thymic carcinoma recurring 11&#x000a0;years post-extended surgery: a case report</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Okamoto</surname><given-names>Kiyoki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kanou</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kawagishi</surname><given-names>Sachi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nagata</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Morii</surname><given-names>Eiichi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2540-5288</contrib-id><name><surname>Shintani</surname><given-names>Yasushi</given-names></name><address><email>yshintani@thoracic.med.osaka-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035t8zc32</institution-id><institution-id institution-id-type="GRID">grid.136593.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0373 3971</institution-id><institution>Department of General Thoracic Surgery, </institution><institution>Osaka University Graduate School of Medicine, </institution></institution-wrap>2-2 Yamadaoka, Suita, Osaka 565-0871 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035t8zc32</institution-id><institution-id institution-id-type="GRID">grid.136593.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0373 3971</institution-id><institution>Department of Pathology, </institution><institution>Osaka University Graduate School of Medicine, </institution></institution-wrap>Osaka, Japan </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>4</volume><elocation-id>9</elocation-id><history><date date-type="received"><day>10</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Thymic carcinoma is a rare type of tumor originating in the thymus, making up about 15&#x02013;20% of all thymic epithelial tumors. It typically has a poor prognosis, especially in advanced stages, with low 5-year survival rates. Cases where the cancer recurs more than 10&#x000a0;years after surgery are extremely uncommon. Additionally, there are very few reports about the outcomes of patients who undergo aortic resection as part of their treatment for thymic carcinoma.</p></sec><sec><title>Case presentation</title><p id="Par2">A 68-year-old male was diagnosed with thymic squamous cell carcinoma classified as Masaoka stage III following the detection of an anterior mediastinal mass during a routine health examination. The patient underwent preoperative treatment, which included two cycles of chemotherapy (cisplatin and docetaxel) and 60&#x000a0;Gy of mediastinal radiotherapy, followed by an extensive surgical procedure comprising extended thymectomy, resection of the ascending aorta and superior vena cava, and wedge resection of the right upper lobe. Postoperative pathological examination revealed ypT3N0M0 disease, corresponding to ypStage IIIa disease, and the patient remained disease-free for 10&#x000a0;years. However, at 11&#x000a0;years after surgery, imaging revealed new nodules in the left lung. Surgical resection confirmed these nodules as metastatic lesions originating from the thymic carcinoma.</p></sec><sec><title>Conclusions</title><p id="Par3">This case highlights the critical need for long-term monitoring of thymic carcinoma patients, extending beyond the standard 5-year follow-up due to the potential for late recurrence, even in initially disease-free patients. Furthermore, our findings indicate that aortic resection, when carefully selected, can contribute to favorable long-term outcomes in advanced cases. This report enhances the limited literature on the long-term prognosis of thymic carcinoma, particularly following major vascular resection, and underscores the importance of a multidisciplinary approach to optimize patient management and improve outcomes.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Thymic carcinoma</kwd><kwd>Long-term recurrence</kwd><kwd>Aorta</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Japanese Association for Thoracic Surgery 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par8">Thymic carcinoma is an uncommon type of thymic epithelial tumor, accounting for approximately 10&#x02013;15% of all thymic tumors [<xref ref-type="bibr" rid="CR1">1</xref>]. Patients diagnosed with advanced stages of this cancer face a challenging prognosis, and it is known as a disease with a poor prognosis. Complete resection is a prognostic factor for thymic carcinoma [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]; however, recurrence can still occur even after complete resection. Reports of initial recurrence occurring more than 10&#x000a0;years postoperatively are extremely rare [<xref ref-type="bibr" rid="CR5">5</xref>]. Herein, we report a case of thymic carcinoma that recurred more than 10&#x000a0;years after complete resection through trimodal treatment including extensive surgery which we previously reported [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec2"><title>Case presentation</title><p id="Par9">A 68-year-old male who presented to our hospital after a routine health check revealed an abnormal shadow on his chest radiograph. Contrast-enhanced chest computed tomography (CT) revealed an anterior mediastinal mass (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A CT-guided needle biopsy was performed via a vertical approach through the left parasternal space and confirmed the diagnosis of thymic squamous cell carcinoma which was classified as Masaoka stage III (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). As part of the preoperative treatment, the patient underwent two cycles of chemotherapy with cisplatin and docetaxel, along with 60 Gy of mediastinal radiotherapy. Following this treatment, we performed extended thymectomy combined with resection of the ascending aorta and superior vena cava (SVC), wedge resection of the right upper lobe, replacement of the ascending aorta, and SVC reconstruction [<xref ref-type="bibr" rid="CR6">6</xref>]. Permanent pathological examination confirmed the diagnosis of squamous cell carcinoma with tumor invasion into the SVC wall and adjacent tumor cells to the aortic wall (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). No malignancy was detected in the regional lymph nodes or pericardium. Based on these findings, the tumor was staged as ypT3N0M0, ypStage IIIa according to the American Joint Committee on Cancer 8th Edition criteria, which is consistent with Masaoka stage III.<fig id="Fig1"><label>Fig. 1</label><caption><p>Initial contrast-enhanced chest CT image showing an irregular 8.4&#x02009;&#x000d7;&#x02009;6.0&#x000a0;cm mass in the anterior mediastinum. The mass abuts the ascending aorta and compresses the SVC, suggesting invasion</p></caption><graphic xlink:href="44215_2025_190_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>CT-guided needle biopsy was performed for diagnostic purposes. Pathological findings revealed tumor cells with prominent nucleoli and eosinophilic cytoplasm arranged in a cobblestone pattern, with areas of keratinization (<bold>A</bold>). Immunohistochemistry demonstrated p63 positive (<bold>B</bold>), CD117 (c-kit) positive (<bold>C</bold>), and TdT negative (<bold>D</bold>), supporting a diagnosis of thymic squamous cell carcinoma</p></caption><graphic xlink:href="44215_2025_190_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Initial postoperative pathological findings showing typical cells with coarse chromatin and prominent nucleoli proliferating in nests with invasion into the SVC wall (<bold>A</bold>, <bold>B</bold>)</p></caption><graphic xlink:href="44215_2025_190_Fig3_HTML" id="MO3"/></fig></p><p id="Par10">The patient was monitored with contrast-enhanced CT every 6&#x000a0;months until the fifth postoperative year, and annually thereafter and remained disease-free for 10 years postoperatively. However, in the 11th postoperative year, plain chest CT conducted at his local clinic revealed increased right pleural effusion and multiple nodules in the left lung. The patient was subsequently referred to our department for further investigation and management. Upon admission, all hematological and biochemical parameters were within normal limits. The levels of tumor markers, including CEA (2.0 ng/mL), CYFRA (0.7 ng/mL), and ProGRP (35.1 pg/mL), were also within normal ranges. Contrast-enhanced chest CT revealed two solid nodules in the lingular segment of the left lung (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), whereas positron emission tomography (PET)-CT demonstrated fluorodeoxyglucose uptake with a maximum standardized uptake value (SUVmax) of 3.4 in these nodules. The right pleural effusion showed no abnormal uptake (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>), and contrast-enhanced brain CT revealed no evidence of brain metastasis. On the basis of these findings, metastasis from thymic carcinoma was highly suspected as the primary diagnosis, although differential considerations included secondary pulmonary metastasis from another organ&#x02019;s primary cancer, primary lung cancer, and inflammatory nodules. After these potential diagnoses were evaluated, since the right pleural effusion was minimal and a sufficient amount of tissue was deemed necessary for a detailed diagnosis, we proceeded with diagnostic resection of the lung lesions. Given the previous right lung resection and anticipated severe adhesions, we initially opted to perform resection on the left lung nodules. The surgery was conducted under general anesthesia via a completely thoracoscopic approach. After extensive adhesiolysis within the thoracic cavity, only one of the two tumors in the lingular segment of the left lung was palpated and resected using an automatic stapler. The operation lasted 65 min with minimal blood loss. The patient&#x02019;s postoperative recovery was uneventful, and he was discharged home on postoperative day 8.<fig id="Fig4"><label>Fig. 4</label><caption><p>Contrast-enhanced chest CT image taken before the second surgery showing two solid nodules in the left lung lingular segment measuring 8&#x02009;&#x000d7;&#x02009;7&#x000a0;mm (<bold>A</bold>) and 7&#x02009;&#x000d7;&#x02009;5&#x000a0;mm (<bold>B</bold>), with a small amount of right pleural effusion (<bold>C</bold>)</p></caption><graphic xlink:href="44215_2025_190_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Fig. 5</label><caption><p>PET-CT at recurrence revealed an SUVmax of 3.4 for two small nodules in the left lung lingular segment (<bold>A</bold>, <bold>B</bold>). A small amount of right pleural effusion without abnormal uptake was also observed (<bold>C</bold>)</p></caption><graphic xlink:href="44215_2025_190_Fig5_HTML" id="MO5"/></fig></p><p id="Par11">Histopathological examination of the resected specimen revealed findings consistent with metastatic thymic carcinoma (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). The nodule in the left lung lingular segment was thus confirmed as a metastatic lesion from thymic carcinoma. Given the clinical context, another nodule in the lingular segment of the left lung and right pleural effusion was also regarded as metastases of thymic carcinoma. A multidisciplinary team conference recommended the initiation of systemic chemotherapy, and the patient is currently receiving chemotherapy (carboplatin&#x02009;+&#x02009;paclitaxel) at his primary care facility. If disease progression is observed, lenvatinib should be considered the next line of therapy.<fig id="Fig6"><label>Fig. 6</label><caption><p>Pathological findings at the time of the second surgery via hematoxylin and eosin staining demonstrating that tumor cells with nuclear atypia proliferate in nests and are distinctly demarcated from the surrounding normal lung tissue (<bold>A</bold>, <bold>B</bold>) Immunohistochemical staining revealed positive results for CD117 (c-kit) (<bold>C</bold>) and p40 (<bold>D</bold>), which aligned with the characteristics of known thymic carcinoma metastases</p></caption><graphic xlink:href="44215_2025_190_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec3"><title>Discussion</title><p id="Par12">Thymic carcinomas are often large and infiltrate surrounding organs at the time of discovery. Consequently, many cases are in advanced stages (Masaoka stage III or IV) at diagnosis, with recent reports suggesting an overall 5-year survival rate of 36&#x02013;61.1%, making it a disease with a poor prognosis [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The complete resection of thymic carcinoma has improved the 5-year survival rate to 58&#x02013;85.1%, confirming the importance of surgical intervention [<xref ref-type="bibr" rid="CR9">9</xref>]. Additionally, preoperative and postoperative chemotherapy and radiotherapy have been shown to improve survival, emphasizing the importance of multidisciplinary treatment, which includes surgery, chemotherapy, and radiotherapy [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par13">In this case, long-term survival was achieved after complete resection with combined resection of the aortic arch and superior vena cava for advanced-stage thymic carcinoma (Masaoka stage III) following preoperative chemoradiotherapy, with distant metastasis occurring 11&#x000a0;years postoperatively. Yau-Lin et al. reported that tumor infiltration of the superior vena cava, pulmonary artery, and aorta are poor prognostic factors after surgery for thymic carcinoma [<xref ref-type="bibr" rid="CR11">11</xref>]. However, there have been few reports on long-term outcomes after thymic carcinoma resection with aortic resection. In our review of the literature, there are only five reported cases regarding the prognosis after thymic cancer surgery involving concomitant resection of the aorta, and most studies provide only short-term disease-free survival data (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. We present six cases from our institution including cases which we previously reported (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Among these patients, the average age was 60&#x000a0;years (range,45&#x02013;74; median, 60), with 4 males and 2 females. Clinically, 3 patients had Masaoka stage III disease, and 3 had stage IV disease; all patients underwent surgery and R0 resection was achieved in all patients. The postoperative observation period ranged from 4&#x000a0;months to 11&#x000a0;years and 5&#x000a0;months, with 3 patients experiencing recurrence and no deaths during the observation period. Although aortic resection during thymic carcinoma surgery is often avoided because of the high complication and surgical mortality rates, long-term survival beyond 5&#x000a0;years was achieved in five cases, including two cases exceeding 10&#x000a0;years, suggesting that aortic resection can be a viable option when carefully considered. No fatal postoperative complications were observed in our patients, indicating that case selection was appropriate.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Previously reported cases of thymic carcinoma with combined aortic resection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author</th><th align="left">pMasaoka stage</th><th align="left">pTNM</th><th align="left">pStage</th><th align="left">Combined resected organs</th><th align="left">Resection</th><th align="left">Recurrence</th><th align="left">Outcome</th><th align="left">Preoperative therapy</th><th align="left">Postoperative therapy
</th></tr></thead><tbody><tr><td align="left">Oyama [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">III</td><td align="left">unknown</td><td align="left">unknown</td><td align="left">Ao arch wedge, Lt. S3</td><td align="left">R0</td><td align="left">None</td><td align="left">11&#x000a0;m</td><td align="left">CDDP&#x02009;+&#x02009;BLM&#x02009;+&#x02009;VLB, RT</td><td align="left">None</td></tr><tr><td align="left">Takahashi [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">III</td><td align="left">pT4N0M0</td><td align="left">IIIb</td><td align="left">Ao arch, BCA, Lt. CCA, Lt. SCA, Lt. BCV, LUL, Lt. VN</td><td align="left">R0</td><td align="left">13&#x000a0;m (anterior mediastinum)</td><td align="left">Unknown</td><td align="left">CP, RT</td><td align="left">RT</td></tr><tr><td align="left">Michael Ried 1 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">III</td><td align="left">pT4N0M0</td><td align="left">IIIb</td><td align="left">Ao arch, main PA, Lt. BCV</td><td align="left">R2</td><td align="left">Increase in residual tumor</td><td align="left">7&#x000a0;m dead</td><td align="left">PAC</td><td align="left">None</td></tr><tr><td align="left">Michael Ried 2 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">III</td><td align="left">pT4N0M0</td><td align="left">IIIb</td><td align="left">Ao arch, BCA, Lt. CCA, Lt. SCA, Lt. BCV, RUL wedge, LUL wedge</td><td align="left">R0</td><td align="left">None</td><td align="left">8&#x000a0;m</td><td align="left">PAC</td><td align="left">None</td></tr><tr><td align="left">Oka [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">III</td><td align="left">pT4N0M0</td><td align="left">IIIb</td><td align="left">Ao arch, BCA, Lt. CCA, Lt. SCA, Lt. BCV, LUL, Lt. VN</td><td align="left">R0</td><td align="left">None</td><td align="left">3 y</td><td align="left">none</td><td align="left">None</td></tr></tbody></table><table-wrap-foot><p><italic>Ao</italic>, aorta; <italic>BCA</italic>, brachiocephalic artery; <italic>CCA</italic>, common carotid artery; <italic>SCA</italic>, subclavian artery; <italic>PA</italic>, pulmonary artery; <italic>BCV</italic>, brachiocephalic vein; <italic>RUL</italic>, right upper lobe; <italic>Rt</italic>, right, <italic>Lt</italic>, left; <italic>LUL</italic>, left upper lobe; <italic>VN</italic>, vagus nerve; <italic>m</italic>, month; <italic>y</italic>, year; <italic>CDDP</italic>, cisplatin; <italic>BLM</italic>, bleomycine; <italic>VLB</italic>,vinblastine; <italic>RT</italic>, radiation therapy; <italic>CP</italic>, carboplatin&#x02009;+&#x02009;paclitaxel; <italic>PAC</italic>, cisplatin&#x02009;+&#x02009;doxorubicin&#x02009;+&#x02009;cyclophosphamid</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Summary of thymic carcinoma cases undergoing combined aortic resection at our institution</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case</th><th align="left">Age</th><th align="left">Sex</th><th align="left">Histological type</th><th align="left">cMasaoka stage</th><th align="left">cTNM</th><th align="left">Preoperative therapy</th><th align="left">Combined Resected Organs</th><th align="left">ypTNM</th><th align="left">ypStage</th><th align="left">Postoperative therapy</th><th align="left">Recurrence</th><th align="left">Recurrence therapy</th><th align="left">Outcome</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">57</td><td align="left">M</td><td align="left">Sq</td><td align="left">IVb</td><td align="left">T4N2M0</td><td align="left">CDDP&#x02009;+&#x02009;DTX, RT</td><td align="left">Ao arch, SVC, RUL wedge</td><td align="left">T4N0M0</td><td align="left">IIIb</td><td align="left">none</td><td align="left">11 y 2&#x000a0;m (Lt. lung)</td><td align="left">CP</td><td align="left">11 y 5&#x000a0;m</td></tr><tr><td align="left">2</td><td align="left">65</td><td align="left">F</td><td align="left">Sq</td><td align="left">III</td><td align="left">T4N0M0</td><td align="left">CP, RT</td><td align="left">Ao arch, Rt. VN, Rt. PN</td><td align="left">T1bN0M0</td><td align="left">I</td><td align="left">none</td><td align="left">3 y 0&#x000a0;m (Lt. thyroid gland)</td><td align="left">CP (PD)&#x02009;&#x02192;&#x02009;Lenvatinib<sup>a</sup> (SD)</td><td align="left">10 y 7&#x000a0;m</td></tr><tr><td align="left">3 [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">74</td><td align="left">M</td><td align="left">Sq</td><td align="left">III</td><td align="left">T4N0M0</td><td align="left">ADOC&#x02009;&#x02192;&#x02009;CP</td><td align="left">Ao arch&#x03001;Lt. VN, Lt. RLN, Lt. PN</td><td align="left">T3N0M0</td><td align="left">IIIa</td><td align="left">none</td><td align="left">None</td><td align="left">none</td><td align="left">7 y</td></tr><tr><td align="left">4 [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="left">45</td><td align="left">M</td><td align="left">Sq</td><td align="left">IVa</td><td align="left">T4N0M1a</td><td align="left">CP&#x02009;&#x02192;&#x02009;TGO</td><td align="left">Ao arch, main PA, Lt. BCV, Lt. Pneumonectomy, Lt. VN, Lt. PN</td><td align="left">T2N0M0</td><td align="left">II</td><td align="left">none</td><td align="left">3 y 1&#x000a0;m (paratracheal lymph nodes)</td><td align="left">RT</td><td align="left">6 y 9&#x000a0;m</td></tr><tr><td align="left">5</td><td align="left">61</td><td align="left">M</td><td align="left">Sq</td><td align="left">III</td><td align="left">T4N0M0</td><td align="left">CP, RT</td><td align="left">Ao arch, LUL, Lt. VN, Lt. PN, Lt. SNT</td><td align="left">T4N0M1a</td><td align="left">IVa</td><td align="left">none</td><td align="left">None</td><td align="left">None</td><td align="left">5 y 8&#x000a0;m</td></tr><tr><td align="left">6</td><td align="left">59</td><td align="left">F</td><td align="left">Sq</td><td align="left">IVa</td><td align="left">T4N0M1a</td><td align="left">CDDP&#x02009;+&#x02009;ETP, RT</td><td align="left">Ao arch, main PA, Lt. BCV, LUL</td><td align="left">T3N0M0</td><td align="left">IIIa</td><td align="left">none</td><td align="left">None</td><td align="left">None</td><td align="left">4&#x000a0;m</td></tr></tbody></table><table-wrap-foot><p><italic>M</italic>, male; <italic>F</italic>, female; <italic>Sq</italic>, squamous cell carcinoma; <italic>CDDP</italic>, cisplatin; <italic>DTX</italic>, doxorubicin; <italic>RT</italic>, radiation therapy; <italic>CP</italic>, carboplatin&#x02009;+&#x02009;paclitaxel; <italic>ADOC</italic>, doxorubicin&#x02009;+&#x02009;cisplatin&#x02009;+&#x02009;vincristine&#x02009;+&#x02009;cyclophosphamide; <italic>TGO</italic>, tegafur&#x02009;+&#x02009;gimeracil&#x02009;+&#x02009;oteracil; <italic>ETP</italic>, etoposide; <italic>Ao</italic>, aorta; <italic>SVC</italic>, superior vena cava; <italic>RUL</italic>, right upper lobe; <italic>VN</italic>, vagus nerve; <italic>PN</italic>, phrenic nerve; <italic>RLN</italic>, reccurent laryngeal nerve; <italic>PA</italic>, pulmonary artery; <italic>BCV</italic>, brachiocephalic vein; <italic>LUL</italic>, left upper lobectomy; <italic>SNT</italic>, sympathetic nerve trunk; <italic>Rt</italic>, right; <italic>Lt</italic>, left; <italic>m</italic>, month; <italic>y</italic>, year</p><p><sup>a</sup>Discontinued due to adverse effects</p></table-wrap-foot></table-wrap></p><p id="Par14">Hishida et al. studied long-term outcomes after surgery for thymic carcinoma and reported significant differences in overall survival and recurrence-free survival between stages I/II and III/IV at both 5 and 10&#x000a0;years postoperatively [<xref ref-type="bibr" rid="CR3">3</xref>]. Previous reports suggest that the risk of disease progression between 5 and 10&#x000a0;years postoperatively is minimal, with Hamaji et al. reporting a median time to first recurrence of 10&#x000a0;months (range, 2&#x02013;54&#x000a0;months) [<xref ref-type="bibr" rid="CR18">18</xref>]. Accordingly, the current Japanese guidelines recommend a follow-up period of more than 5&#x000a0;years after surgery for thymic carcinoma. Retrospective studies have been the main source of reports on the long-term outcomes of thymic carcinoma, and only three cases have reported detailed reports on recurrence after 10&#x000a0;years (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In this case, recurrence occurred 11&#x000a0;years after the initial surgery, prompting reconsideration of the follow-up period for thymic carcinoma after surgery. In other malignancies, factors such as tumor size, age, and lymph node metastasis have been reported as predictors of late recurrence [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. No definitive predictive factors were identified within the cases of this study. However thymic NEC and MEC have been reported in the literature to recur more than 20&#x000a0;years after surgery. Moreover, the cellular origin of late relapse in these patients is believed to be disseminated tumor cells that become reactivated after a prolonged period of dormancy [<xref ref-type="bibr" rid="CR23">23</xref>]. A similar concept may need to be considered in thymic carcinoma as well. Regarding the treatment of recurrence in cases from our institution (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), Case 1 is currently under follow-up shortly after the initiation of chemotherapy. In Case 2, left thyroid metastasis was observed 3&#x000a0;years after surgery, and local control was achieved with radiotherapy. However, bilateral pulmonary metastases were identified 6&#x000a0;years and 6&#x000a0;months postoperatively. Chemotherapy was initiated but resulted in progressive disease. Following the initiation of lenvatinib therapy, the patient has achieved stable disease for seven years. In Case 4, paratracheal lymph node metastasis was observed 3&#x000a0;years and 1&#x000a0;month postoperatively, and local control was successfully achieved with radiotherapy. Considering these cases, systemic therapy with novel agents and local treatments for oligometastases may also be effective in managing postoperative recurrence of thymic carcinoma. These findings support the necessity of long-term follow-up for advanced thymic carcinoma.
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Case series of thymic carcinoma recurring more than 10&#x000a0;years after surgical resection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author</th><th align="left">Histological type</th><th align="left">Preoperative therapy</th><th align="left">Prosedure</th><th align="left">Resection</th><th align="left">pMasaoka stage</th><th align="left">Postoperative therapy</th><th align="left">Recurrence interval</th><th align="left">Recurrence site</th><th align="left">Recurrence therapy</th></tr></thead><tbody><tr><td align="left">Toyokawa [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left">NEC</td><td align="left">unknown</td><td align="left">Thymectomy</td><td align="left">R1</td><td align="left">I</td><td align="left">None</td><td align="left">24 y</td><td align="left">Local reccurrence</td><td align="left">None</td></tr><tr><td align="left">Yabuki [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td align="left">Sq</td><td align="left">none</td><td align="left">Thymectomy&#x02009;+&#x02009;LUL Wedge</td><td align="left">R0</td><td align="left">III</td><td align="left">CDDP&#x02009;+&#x02009;ETP, RT</td><td align="left">10 y</td><td align="left">Lt. malignant pleural effusion</td><td align="left">CP</td></tr><tr><td align="left">Hayashi [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">MEC</td><td align="left">none</td><td align="left">Extended thymenctomy&#x02009;+&#x02009;RUL Wedge</td><td align="left">R0</td><td align="left">III</td><td align="left">None</td><td align="left">21 y</td><td align="left">Rt. pleural dissemination</td><td align="left">None</td></tr></tbody></table><table-wrap-foot><p><italic>NEC</italic>, neuroendocrine carcinoma; <italic>Sq</italic>, squamous cell carcinoma, <italic>MEC</italic>, mucoepidermoid carcinoma; <italic>LUL</italic>, left upper lobe; <italic>RUL</italic>, right upper lobe; <italic>CDDP</italic>, cisplatin; <italic>ETP</italic>, etoposide; <italic>RT</italic>, radiation therapy; <italic>y</italic>, year; <italic>Lt</italic>, left; <italic>Rt</italic>, right; <italic>CP</italic>, carboplatin&#x02009;+&#x02009;paclitaxel</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Conclusions</title><p id="Par15">For advanced thymic carcinoma, follow-up for more than 10&#x000a0;years may be considered even after complete resection. Additionally, aggressive thymic carcinoma resection, including aortic resection, may achieve favorable long-term outcomes when combined with appropriate techniques and careful patient selection.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CT</term><def><p id="Par4">Computed tomography</p></def></def-item><def-item><term>PET</term><def><p id="Par5">Positron emission tomography</p></def></def-item><def-item><term>SUVmax</term><def><p id="Par6">Maximum standardized uptake value</p></def></def-item><def-item><term>SVC</term><def><p id="Par7">Superior vena cava</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>KO wrote the manuscript and contributed to the creation of the figures and tables. YS supervised and authorized this study. SK performed the operation with TK. HN and EM performed the pathological examination and diagnosis. All authors read and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study did not receive any funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par16">The study protocol was approved by the Ethical Review Board for Clinical Studies of Osaka University Hospital (control number: 10026).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par17">A written informed consent was obtained from the patient for the publication of this case report and accompanying images.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par18">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruffini</surname><given-names>E</given-names></name><name><surname>Detterbeck</surname><given-names>F</given-names></name><name><surname>Van Raemdonck</surname><given-names>D</given-names></name><name><surname>Rocco</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Weder</surname><given-names>W</given-names></name><name><surname>Brunelli</surname><given-names>A</given-names></name><name><surname>Guerrera</surname><given-names>F</given-names></name><name><surname>Keshavjee</surname><given-names>S</given-names></name><name><surname>Altorki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database</article-title><source>J Thorac Oncol</source><year>2014</year><volume>9</volume><fpage>541</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000128</pub-id><pub-id pub-id-type="pmid">24736078</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, Brunelli A, Guerrera F, Keshavjee S, Altorki N, et al. Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database. J Thorac Oncol. 2014;9:541&#x02013;8. 10.1097/JTO.0000000000000128.<pub-id pub-id-type="pmid">24736078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Weksler</surname><given-names>B</given-names></name><name><surname>Dhupar</surname><given-names>R</given-names></name><name><surname>Parikh</surname><given-names>V</given-names></name><name><surname>Nason</surname><given-names>KS</given-names></name><name><surname>Pennathur</surname><given-names>A</given-names></name><name><surname>Ferson</surname><given-names>PF</given-names></name></person-group><article-title>Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients</article-title><source>Ann Thorac Surg</source><year>2013</year><volume>95</volume><fpage>299</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2012.09.006</pub-id><pub-id pub-id-type="pmid">23141529</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF. Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg. 2013;95:299&#x02013;303. 10.1016/j.athoracsur.2012.09.006.<pub-id pub-id-type="pmid">23141529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Hishida</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>S</given-names></name><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Asamura</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Ohde</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Date</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name><etal/></person-group><article-title>Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study</article-title><source>Eur J Cardiothorac Surg</source><year>2016</year><volume>49</volume><fpage>835</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezv239</pub-id><pub-id pub-id-type="pmid">26116920</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Hishida T, Nomura S, Yano M, Asamura H, Yamashita M, Ohde Y, Kondo K, Date H, Okumura M, Nagai K, et al. Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. Eur J Cardiothorac Surg. 2016;49:835&#x02013;41. 10.1093/ejcts/ezv239.<pub-id pub-id-type="pmid">26116920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>ZT</given-names></name><name><surname>Fang</surname><given-names>WT</given-names></name><name><surname>Fu</surname><given-names>JH</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>YT</given-names></name><name><surname>Yu</surname><given-names>ZT</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>LJ</given-names></name><name><surname>Pang</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Long-term survival after surgical treatment of thymic carcinoma: a retrospective analysis from the chinese alliance for research of thymoma database</article-title><source>Ann Surg Oncol</source><year>2016</year><volume>23</volume><fpage>619</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1245/s10434-015-4825-4</pub-id><pub-id pub-id-type="pmid">26474558</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Fu H, Gu ZT, Fang WT, Fu JH, Shen Y, Han YT, Yu ZT, Li Y, Tan LJ, Pang LW, et al. Long-term survival after surgical treatment of thymic carcinoma: a retrospective analysis from the chinese alliance for research of thymoma database. Ann Surg Oncol. 2016;23:619&#x02013;25. 10.1245/s10434-015-4825-4.<pub-id pub-id-type="pmid">26474558</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Yabuki</surname><given-names>H</given-names></name><name><surname>Minowa</surname><given-names>M</given-names></name></person-group><article-title>Long survival and recurrence of thymic carcinoma 10 years after resection</article-title><source>Asian Cardiovasc Thorac Ann</source><year>2019</year><volume>27</volume><fpage>407</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1177/0218492319848958</pub-id><pub-id pub-id-type="pmid">31064197</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Yabuki H, Minowa M. Long survival and recurrence of thymic carcinoma 10 years after resection. Asian Cardiovasc Thorac Ann. 2019;27:407&#x02013;9. 10.1177/0218492319848958.<pub-id pub-id-type="pmid">31064197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Momozane</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Shintani</surname><given-names>Y</given-names></name><name><surname>Funaki</surname><given-names>S</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Minami</surname><given-names>M</given-names></name><name><surname>Shirakawa</surname><given-names>Y</given-names></name><name><surname>Kuratani</surname><given-names>T</given-names></name><name><surname>Sawa</surname><given-names>Y</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name></person-group><article-title>Trimodality therapy for an advanced thymic carcinoma with both aorta and vena cava invasion</article-title><source>Ann Thorac Surg</source><year>2016</year><volume>102</volume><fpage>E139</fpage><lpage>E141</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2016.01.014</pub-id><pub-id pub-id-type="pmid">27449450</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Momozane T, Inoue M, Shintani Y, Funaki S, Kawamura T, Minami M, Shirakawa Y, Kuratani T, Sawa Y, Okumura M. Trimodality therapy for an advanced thymic carcinoma with both aorta and vena cava invasion. Ann Thorac Surg. 2016;102:E139&#x02013;41. 10.1016/j.athoracsur.2016.01.014.<pub-id pub-id-type="pmid">27449450</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>ZJ</given-names></name><name><surname>Jing</surname><given-names>CB</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>YP</given-names></name></person-group><article-title>The incidence and prognosis of thymic squamous cell carcinoma: a surveillance, epidemiology, and end results program population-based study</article-title><source>Medicine</source><year>2021</year><volume>100</volume><fpage>ARTN e25331</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000025331</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wu JY, Wang ZJ, Jing CB, Hu Y, Yang B, Hu YP. The incidence and prognosis of thymic squamous cell carcinoma: a surveillance, epidemiology, and end results program population-based study. Medicine. 2021;100:ARTN e25331. 10.1097/MD.0000000000025331.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Hosaka</surname><given-names>Y</given-names></name><name><surname>Tsuchida</surname><given-names>M</given-names></name><name><surname>Toyabe</surname><given-names>S</given-names></name><name><surname>Umezu</surname><given-names>H</given-names></name><name><surname>Eimoto</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>J</given-names></name></person-group><article-title>Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>89</volume><fpage>912</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2009.11.057</pub-id><pub-id pub-id-type="pmid">20172153</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hosaka Y, Tsuchida M, Toyabe S, Umezu H, Eimoto T, Hayashi J. Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg. 2010;89:912&#x02013;7. 10.1016/j.athoracsur.2009.11.057.<pub-id pub-id-type="pmid">20172153</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CY</given-names></name><name><surname>Bae</surname><given-names>MK</given-names></name><name><surname>Park</surname><given-names>IK</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Lee</surname><given-names>JG</given-names></name><name><surname>Chung</surname><given-names>KY</given-names></name></person-group><article-title>Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution</article-title><source>Eur J Cardio-Thorac</source><year>2009</year><volume>36</volume><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.ejcts.2009.02.019</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Chung KY. Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution. Eur J Cardio-Thorac. 2009;36:159&#x02013;63. 10.1016/j.ejcts.2009.02.019.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Shintani</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Funaki</surname><given-names>S</given-names></name><name><surname>Minami</surname><given-names>M</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name></person-group><article-title>Multimodality treatment for advanced thymic carcinoma: outcomes of induction therapy followed by surgical resection in 16 cases at a single institution</article-title><source>Gen Thorac Cardiovasc Surg</source><year>2015</year><volume>63</volume><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1007/s11748-014-0486-7</pub-id><pub-id pub-id-type="pmid">25311849</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Shintani Y, Inoue M, Kawamura T, Funaki S, Minami M, Okumura M. Multimodality treatment for advanced thymic carcinoma: outcomes of induction therapy followed by surgical resection in 16 cases at a single institution. Gen Thorac Cardiovasc Surg. 2015;63:159&#x02013;63. 10.1007/s11748-014-0486-7.<pub-id pub-id-type="pmid">25311849</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>YL</given-names></name><name><surname>Wang</surname><given-names>ST</given-names></name><name><surname>Wu</surname><given-names>MH</given-names></name><name><surname>Lin</surname><given-names>MY</given-names></name><name><surname>Lai</surname><given-names>WW</given-names></name><name><surname>Cheng</surname><given-names>FF</given-names></name></person-group><article-title>Thymic carcinoma: involvement of great vessels indicates poor prognosis</article-title><source>Ann Thorac Surg</source><year>2003</year><volume>76</volume><fpage>1041</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1016/s0003-4975(03)00831-2</pub-id><pub-id pub-id-type="pmid">14529981</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tseng YL, Wang ST, Wu MH, Lin MY, Lai WW, Cheng FF. Thymic carcinoma: involvement of great vessels indicates poor prognosis. Ann Thorac Surg. 2003;76:1041&#x02013;5. 10.1016/s0003-4975(03)00831-2.<pub-id pub-id-type="pmid">14529981</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname><given-names>K</given-names></name><name><surname>Onuki</surname><given-names>T</given-names></name><name><surname>Mae</surname><given-names>M</given-names></name><name><surname>Adachi</surname><given-names>T</given-names></name><name><surname>Kanzaki</surname><given-names>M</given-names></name><name><surname>Murasugi</surname><given-names>M</given-names></name><name><surname>Sone</surname><given-names>Y</given-names></name><name><surname>Kei</surname><given-names>J</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Nitta</surname><given-names>S</given-names></name></person-group><article-title>Combined thoracic aortic or upper digestive tract resection for lung cancer and malignant mediastinal tumor</article-title><source>Jpn J Thorac Cardiovasc Surg</source><year>2000</year><volume>48</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/BF03218079</pub-id><pub-id pub-id-type="pmid">10714015</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Oyama K, Onuki T, Mae M, Adachi T, Kanzaki M, Murasugi M, Sone Y, Kei J, Yokoyama M, Nitta S. Combined thoracic aortic or upper digestive tract resection for lung cancer and malignant mediastinal tumor. Jpn J Thorac Cardiovasc Surg. 2000;48:9&#x02013;15. 10.1007/BF03218079.<pub-id pub-id-type="pmid">10714015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Takinami</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Kazui</surname><given-names>T</given-names></name></person-group><article-title>Aortic arch resection under temporary bypass grafting for advanced thymic cancer</article-title><source>Jpn J Thorac Cardiovasc Surg</source><year>2002</year><volume>50</volume><fpage>302</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1007/BF03032300</pub-id><pub-id pub-id-type="pmid">12166271</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Takahashi T, Suzuki K, Ito Y, Takinami M, Yamashita K, Kazui T. Aortic arch resection under temporary bypass grafting for advanced thymic cancer. Jpn J Thorac Cardiovasc Surg. 2002;50:302&#x02013;4. 10.1007/BF03032300.<pub-id pub-id-type="pmid">12166271</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Ried</surname><given-names>M</given-names></name><name><surname>Neu</surname><given-names>R</given-names></name><name><surname>Schalke</surname><given-names>B</given-names></name><name><surname>von Susskind-Schwendi</surname><given-names>M</given-names></name><name><surname>Sziklavari</surname><given-names>Z</given-names></name><name><surname>Hofmann</surname><given-names>HS</given-names></name></person-group><article-title>Radical surgical resection of advanced thymoma and thymic carcinoma infiltrating the heart or great vessels with cardiopulmonary bypass support</article-title><source>J Cardiothorac Surg</source><year>2015</year><volume>10</volume><fpage>137</fpage><pub-id pub-id-type="doi">10.1186/s13019-015-0346-2</pub-id><pub-id pub-id-type="pmid">26515387</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ried M, Neu R, Schalke B, von Susskind-Schwendi M, Sziklavari Z, Hofmann HS. Radical surgical resection of advanced thymoma and thymic carcinoma infiltrating the heart or great vessels with cardiopulmonary bypass support. J Cardiothorac Surg. 2015;10:137. 10.1186/s13019-015-0346-2.<pub-id pub-id-type="pmid">26515387</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Oka</surname><given-names>S</given-names></name><name><surname>Taira</surname><given-names>A</given-names></name><name><surname>Shinohara</surname><given-names>S</given-names></name><name><surname>Kuwata</surname><given-names>T</given-names></name><name><surname>Takenaka</surname><given-names>M</given-names></name><name><surname>Chikaishi</surname><given-names>Y</given-names></name><name><surname>Hirai</surname><given-names>A</given-names></name><name><surname>Uramoto</surname><given-names>H</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>F</given-names></name></person-group><article-title>Complete resection of thymic sarcomatoid carcinoma through total aortic arch replacement</article-title><source>Ann Thorac Surg</source><year>2016</year><volume>102</volume><fpage>E557</fpage><lpage>E559</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2016.05.095</pub-id><pub-id pub-id-type="pmid">27847081</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Oka S, Taira A, Shinohara S, Kuwata T, Takenaka M, Chikaishi Y, Hirai A, Uramoto H, Nishimura Y, Tanaka F. Complete resection of thymic sarcomatoid carcinoma through total aortic arch replacement. Ann Thorac Surg. 2016;102:E557&#x02013;9. 10.1016/j.athoracsur.2016.05.095.<pub-id pub-id-type="pmid">27847081</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuno</surname><given-names>H</given-names></name><name><surname>Funaki</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Shimamura</surname><given-names>K</given-names></name><name><surname>Kin</surname><given-names>K</given-names></name><name><surname>Kuratani</surname><given-names>T</given-names></name><name><surname>Sawa</surname><given-names>Y</given-names></name><name><surname>Shintani</surname><given-names>Y</given-names></name></person-group><article-title>Complete resection of local advanced thymic carcinoma with total aortic arch replacement after chemotherapy: a case report</article-title><source>Surg Case Rep</source><year>2019</year><volume>5</volume><fpage>198</fpage><pub-id pub-id-type="doi">10.1186/s40792-019-0713-7</pub-id><pub-id pub-id-type="pmid">31832805</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kuno H, Funaki S, Kimura K, Shimamura K, Kin K, Kuratani T, Sawa Y, Shintani Y. Complete resection of local advanced thymic carcinoma with total aortic arch replacement after chemotherapy: a case report. Surg Case Rep. 2019;5:198. 10.1186/s40792-019-0713-7.<pub-id pub-id-type="pmid">31832805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamato</surname><given-names>H</given-names></name><name><surname>Funaki</surname><given-names>S</given-names></name><name><surname>Shimamura</surname><given-names>K</given-names></name><name><surname>Kin</surname><given-names>K</given-names></name><name><surname>Kuratani</surname><given-names>T</given-names></name><name><surname>Sawa</surname><given-names>Y</given-names></name><name><surname>Shintani</surname><given-names>Y</given-names></name></person-group><article-title>Salvage surgery for stage IVa thymic carcinoma combined with aortic arch resection - case report</article-title><source>J Cardiothorac Surg</source><year>2020</year><volume>15</volume><fpage>305</fpage><pub-id pub-id-type="doi">10.1186/s13019-020-01354-1</pub-id><pub-id pub-id-type="pmid">33028405</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Yamato H, Funaki S, Shimamura K, Kin K, Kuratani T, Sawa Y, Shintani Y. Salvage surgery for stage IVa thymic carcinoma combined with aortic arch resection - case report. J Cardiothorac Surg. 2020;15:305. 10.1186/s13019-020-01354-1.<pub-id pub-id-type="pmid">33028405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Hamaji M, Allen MS, Cassivi SD, Nichols FC 3rd, Wigle DA, Deschamps C, Shen KR. The role of surgical management in recurrent thymic tumors. Ann Thorac Surg 2012;94:247-254. 10.1016/j.athoracsur.2012.02.092. discussion 254.</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Toyokawa</surname><given-names>G</given-names></name><name><surname>Taguchi</surname><given-names>K</given-names></name><name><surname>Kojo</surname><given-names>M</given-names></name><name><surname>Toyozawa</surname><given-names>R</given-names></name><name><surname>Inamasu</surname><given-names>E</given-names></name><name><surname>Morodomi</surname><given-names>Y</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Takenaka</surname><given-names>T</given-names></name><name><surname>Hirai</surname><given-names>F</given-names></name><name><surname>Yamaguchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Recurrence of thymic neuroendocrine carcinoma 24 years after total excision: a case report</article-title><source>Oncol Lett</source><year>2013</year><volume>6</volume><fpage>147</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.3892/ol.2013.1327</pub-id><pub-id pub-id-type="pmid">23946793</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Toyokawa G, Taguchi K, Kojo M, Toyozawa R, Inamasu E, Morodomi Y, Shiraishi Y, Takenaka T, Hirai F, Yamaguchi M, et al. Recurrence of thymic neuroendocrine carcinoma 24 years after total excision: a case report. Oncol Lett. 2013;6:147&#x02013;9. 10.3892/ol.2013.1327.<pub-id pub-id-type="pmid">23946793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Mikubo</surname><given-names>M</given-names></name><name><surname>Tochimoto</surname><given-names>M</given-names></name><name><surname>Ichinoe</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>Y</given-names></name></person-group><article-title>Pleural recurrence 21 years after complete resection of thymic mucoepidermoid carcinoma: a case report</article-title><source>Gen Thorac Cardiovasc Surg Cases</source><year>2023</year><volume>2</volume><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/s44215-023-00124-4</pub-id><pub-id pub-id-type="pmid">39516971</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hayashi S, Matsushima K, Mikubo M, Tochimoto M, Ichinoe M, Satoh Y. Pleural recurrence 21 years after complete resection of thymic mucoepidermoid carcinoma: a case report. Gen Thorac Cardiovasc Surg Cases. 2023;2:105. 10.1186/s44215-023-00124-4.<pub-id pub-id-type="pmid">39516971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kwak</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>HH</given-names></name><name><surname>Jung</surname><given-names>JH</given-names></name><name><surname>Ku</surname><given-names>JH</given-names></name></person-group><article-title>Late Recurrence of bladder cancer following radical cystectomy: characteristics and outcomes</article-title><source>Urol Int</source><year>2019</year><volume>103</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1159/000502656</pub-id><pub-id pub-id-type="pmid">31461728</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Yoo SH, Kim H, Kwak C, Kim HH, Jung JH, Ku JH. Late Recurrence of bladder cancer following radical cystectomy: characteristics and outcomes. Urol Int. 2019;103:291&#x02013;6. 10.1159/000502656.<pub-id pub-id-type="pmid">31461728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>RN</given-names></name><name><surname>Esen</surname><given-names>BO</given-names></name><name><surname>Mellemkjaer</surname><given-names>L</given-names></name><name><surname>Christiansen</surname><given-names>P</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Lash</surname><given-names>TL</given-names></name><name><surname>Norgaard</surname><given-names>M</given-names></name><name><surname>Cronin-Fenton</surname><given-names>D</given-names></name></person-group><article-title>The incidence of breast cancer recurrence 10&#x02013;32 years after primary diagnosis</article-title><source>J Natl Cancer Inst</source><year>2022</year><volume>114</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1093/jnci/djab202</pub-id><pub-id pub-id-type="pmid">34747484</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Pedersen RN, Esen BO, Mellemkjaer L, Christiansen P, Ejlertsen B, Lash TL, Norgaard M, Cronin-Fenton D. The incidence of breast cancer recurrence 10&#x02013;32 years after primary diagnosis. J Natl Cancer Inst. 2022;114:391&#x02013;9. 10.1093/jnci/djab202.<pub-id pub-id-type="pmid">34747484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Sosa</surname><given-names>MS</given-names></name><name><surname>Bragado</surname><given-names>P</given-names></name><name><surname>Aguirre-Ghiso</surname><given-names>JA</given-names></name></person-group><article-title>Mechanisms of disseminated cancer cell dormancy: an awakening field</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/nrc3793</pub-id><pub-id pub-id-type="pmid">25118602</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14:611&#x02013;22. 10.1038/nrc3793.<pub-id pub-id-type="pmid">25118602</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>